NCT02685436

Role of Pepsin Assay in Wheezy Infants

Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Mansoura University Children Hospital · Academic / Other
• Sex: All
• Age: 6 Months – 2 Years
• Healthy volunteers: Not accepted

Summary

Wheezy infants were tested for gastro-esophageal reflux disease (GERD) using combined multiple channel intraluminal impedance-pH (MII-pH), esophagogastroduodenoscope (EGD), lipid laden macrophage index and BAL pepsin. Wheezy infants with abnormal MII-pH or reflux esophagitis were given domperidone and omeprazole then re-evaluated for symptoms control and exacerbations recurrence.

Detailed description

Wheezy infants were tested for gastro-esophageal reflux disease using combined MII-pH, EGD, LLMI and BAL pepsin. Wheezy infants with abnormal MII-pH or reflux esophagitis were given domperidone and omeprazole for 12 weeks then re-evaluated for symptoms control and wheeze exacerbations recurrence.

Conditions

• Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	Omeprazole and domperidone	wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)

Timeline

• Start date: 2013-03-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2016-02-18
• Last updated: 2019-10-07
• Results posted: 2019-10-07